logo
Ireland's Sláintecare health reform risks mission creep, needs clearer vision

Ireland's Sláintecare health reform risks mission creep, needs clearer vision

Euractiv6 days ago
'Sláintecare can mean almost whatever we want it to mean,' said Professor Steve Thomas of Trinity College Dublin. 'There's a danger of mission creep,' he warned. Thomas, who helped draft the original Sláintecare report, said the reform risks losing coherence.
At a healthcare policy conference on 25 June, Prof. Thomas called for a clearer vision of universal healthcare. 'We're still debating eligibility and entitlement eight years on,' he said. 'We need to pin down as quickly as possible our vision.'
Sláintecare, Ireland's national healthcare reform programme, was launched in 2017 in response to long-standing issues in the country's health system. It aims to create a universal, single-tier health service where access to care is based on medical need rather than ability to pay.
While digital health transformation is gathering pace, policymakers, clinicians and economists think the reforms must be more ambitious.
They agree that digital advances must deliver better patient outcomes and improved value for money through a more robustly connected, data-driven healthcare system, but the system remains slow to change and fundamentally dysfunctional.
Prof. Thomas urged policymakers to leverage crises as catalysts for reform. 'COVID was quite helpful in getting extra resources into the health system,' he said. 'But we must protect our workforce. We're expecting a lot from them.'
Sláintecare, the country's flagship universal healthcare reform programme, still lacks a unifying vision in a shifting economic and digital landscape. The path forward is fraught with challenges, including fragmented systems, workforce shortages and demoralisation, and a lack of public engagement.
From analogue to AI
Ricardo Sampaio Paco, Service Improvement Lead at St James's Hospital, offered a compelling case study of how digital tools can transform hospital operations. 'At St James's Hospital, 80% of the discharges in the past were occurring after three in the afternoon,' he said. This bottleneck created a 'ripple effect' that delayed admissions and strained emergency departments.
To address this, the hospital implemented a visual management system that digitised patient flow data and enabled real-time decision-making.
'It's now possible to see … for every patient what their estimated discharge is, the clinical criteria for discharge, the discharge destination and required onward care,' Paco explained. 'You can have this within five seconds after you get in contact with the screen.'
The results were striking: a sharp reduction in late discharges, increased surgical throughput, and improved frailty assessments. 'We're now the best hospital for hip fracture care in Ireland,' Paco said, citing a leap from 7% to 70% compliance with national standards.
General practice, the digital bedrock
While hospitals are making strides, Dr Mike O'Callaghan, Clinical Lead at the Irish College of GPs, stressed that general practice remains the 'foundational' layer of Ireland's digital health ecosystem.
'General practice is where a lot of the volume happens,' he said, noting that GPs handle over 21.5 million consultations annually. 'Continuity of care is continuity of records and vice versa.'
O'Callaghan warned against creating new digital silos. 'If everybody's in charge and there's patient information everywhere, then no one is in charge,' he said. 'We need to have a central repository of all this stuff so that we're all on the same page - including the patients.'
He also highlighted the importance of maintaining and curating electronic medical records. 'It's not good enough to build a big, shiny system. You need to make sure that it's being maintained, because that's how patients are kept safe.'
Telemedicine 2.0
Dr Victor Vicens, Chief Medical Officer at Abi Global Health, argued that traditional telemedicine has failed to deliver on its promise. 'Basically, what it did was put a camera in front of a doctor,' he said. 'The basic unit, which was doctor time, was not changed.'
Abi Global Health is using AI to triage cases, allocate healthcare professionals, and monitor consultation quality. 'Next-generation telemedicine is omnichannel, on-demand and up to three times less costly,' Vicens said. 'This leads to better financial results and better health outcomes.'
The economist's view
Dr Jonathan Briody, a health economist at the Royal College of Surgeons in Ireland, framed digital health as a fiscal imperative. 'Digital health is not an optional thing anymore,' he said. 'It's integral to modern service delivery and group patient outcomes.'
He pointed to the success of virtual wards, such as the one at St Vincent's Hospital, which has treated over 500 patients and saved nearly 4,000 bed days. 'Each hospital bed that we free by a safe virtual consultation provides another bed for someone who needs it,' he said.
With the Health Service Executive's 2025 budget reaching €27 billion, Briody emphasised the shift toward value-based healthcare. 'We're measuring success not by the euro spent or services provided, but by the outcomes achieved per euro.'
Trust, data and the public
Despite the momentum, speakers acknowledged that public trust and digital literacy remain significant barriers.
'Patients are shocked when I can't see their medicines,' said O'Callaghan, referring to the lack of interoperability between GP and out-of-hours systems. 'Patients actually think our digital infrastructure is more cooked than it is.'
Briody added that many patients are unaware they own their health data. 'They're shocked to learn that their data belongs to them. We're just mining it for them.'
Vicens argued that public confidence hinges on transparency and evidence. 'Getting more confidence from the systems relies on doing what science has always done – publishing, providing reliable results, and reliable sources of evidence.'
Inclusion and equity
Digital exclusion was another recurring theme, particularly for older people and refugees.
'Six in ten older people in Ireland are not comfortable online,' said Vicky Harris, Head of Programmes at Age Action. 'Digital First, not Digital Only. Ensure quality services are maintained offline as well as online.'
Dr Hanna Balytska, a Ukrainian doctor now working in Limerick, described how language barriers and outdated communication methods - such as postal letters - led to missed appointments among refugees. 'They always keep their telephone number. They always keep their email,' she said. 'So that's why even in English, if we send something in English, they can translate it.'
Community care, the next frontier
Margaret Curran, General Manager at Caredoc, showcased the SMILE programme, which uses wearable devices and remote monitoring to manage chronic conditions. 'It showed a 41% reduction in ED attendances, 44% reduction in bed night stays, and 87% reduction in unscheduled urgent GP visits,' she said.
Curran emphasised the programme's cost-effectiveness. 'To manage 600 high-need patients, we have 4.5 whole-time equivalent triage nurses,' she said. 'It really pays for itself very early on.'
Michelle O'Hagan, a community pharmacist in Tallaght, called for greater integration of pharmacy services. 'We are the cornerstone of healthcare,' she said. 'We can offer more clinical skills and reduce hospital admissions.'
Ireland's digital health transformation is at a critical juncture. The tools, talent and political will are increasingly in place. But to deliver on the promise of Sláintecare, better care, better access, and better value, policymakers must ensure that digital innovation is inclusive, coherent, and grounded in the lived realities of patients and providers alike.
The foundation of the new health era in Ireland has to be a highly effective, data-driven system. Without it, an ageing population and chronic disease will drain and break Ireland's capacity to care for its citizens, damaging the economy and democracy.
By Brian Maguire
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Preparing Europe for the next cross-border health threats, COVID lessons unpacked
Preparing Europe for the next cross-border health threats, COVID lessons unpacked

Euractiv

time10 hours ago

  • Euractiv

Preparing Europe for the next cross-border health threats, COVID lessons unpacked

For many, the COVID-19 pandemic is a fading memory, but for those working at the coalface of public health, the EU and national governments, it's been seared as an instructive reminder of the need for greater policy infrastructure to support better preparation for future cross-border health security threats. In 2022, the European Commission introduced a Regulation to develop a comprehensive prevention, preparedness and response plan at the EU and member state levels. And in a major step forward, WHO Member States recently took measures to strengthen global collaboration on prevention, preparedness and response to future pandemic threats. Acknowledging that pandemics and epidemics remain significant threats to global public health, Shionogi, together with Euractiv, held a panel discussion on how to tackle the question of preparing Europe for emerging cross-border health threats, in particular, the 'slow pandemic' of antimicrobial resistance (AMR). AMR occurs when germs no longer respond to antimicrobial treatments, and experts argue that further cooperation, transparency and improved procedures are needed to combat the deep-rooted problem. Serious cross-border threats Kicking off the discussion, Antonio Parenti, Director, Public Health, Cancer and Health Security, DG SANTE, European Commission, emphasised the critical role of the Regulation on serious cross-border threats to health (EU 2022/2371) which strengthens EU coordination and collaboration, prevention and preparedness, as well as beefing up different monitoring and surveillance mechanisms, serving as the backbone for future health security preparedness and cross-border health responses He explained that DG SANTE is intensifying collaboration with the relevant internal and external stakeholders through simulation exercises and is intensively working on improving the EU's rapid reaction capabilities, and is addressing the growing threat of AMR with unprecedented co-financing through the EU4Health Programme. Embedding health in the EU's Preparedness Strategy, where health is a vital societal function under the Union Preparedness Strategy, is essential, said Parenti 'Ensuring its resilience means boosting citizen readiness and strengthening civil-military health cooperation. A new Technical Working Group on civil-military collaboration under the Health Security Committee is paving the way for interoperable responses to crises, from pandemics to armed aggression and CBRN threats,' he added. Fragmented approaches Rohit Malpani, Senior Policy Advisor at the Global Antibiotic Research & Development Partnership (GARDP), called on the European Union to take a more proactive and integrated stance in addressing antimicrobial resistance (AMR), warning that current fragmented approaches may fall short in the face of future health crises. Malpani argued that 'The EU should introduce an end-to-end model for which the EU coordinates funding across research, clinical development, manufacturing and access.' He stressed that such a model would help avoid the pitfalls experienced during the COVID-19 pandemic, including shortages of medical technologies and counterproductive competition between member states. 'Instead of setting out incentives and hoping that the private sector will respond with what is required, it is critical that the EU and other countries take an active role in defining its needs and ensuring that those needs are met,' he added. Malpani also emphasised the need for adaptable funding and research models. 'Responding to AMR requires flexible funding, models, and R&D approaches: No single push funding or pull incentive will address all needs,' he said. Drawing on GARDP's experience, he advocated for a diversified strategy that includes developing new antibiotics, repurposing existing treatments, and testing combinations of older generics. He noted that the EU's Health Emergency Preparedness and Response Authority (HERA) is well-positioned to support such a tailored response. Malpani urged the EU to maintain a global perspective. 'While it is critical for the EU to ensure that it can develop and ensure access to key medical technologies to address viral threats and bacterial pathogens of concern, it is also important that it is prioritising threats globally, including against AMR, and for underserved populations such as children and babies,' he said, underscoring the importance of ensuring that new technologies are tested and supported by robust data to effectively curb AMR both within Europe and globally. Strategic and operational coordination Laurent Muschel, Deputy Head of HERA, European Commission, agreed that the EU must adopt a toolbox to cross-border health threats - strengthening strategic and operational coordination through HERA and ensuring readiness via early warning systems, advanced research, stockpiles, and joint procurement. He explained that the upcoming MCM Strategy will focus on innovation, supply chain resilience, and equitable access to vaccines, therapeutics, and diagnostics. Muschel also addressed concerns about AMR. 'AMR is treated with the same urgency as pandemics. HERA is investing in novel solutions like bacteriophage therapies and new classes of antibiotics and supporting SMEs through HERA Invest. I believe the EU must reduce dependency on global supply chains by investing in onshore manufacturing and modernising distribution mechanisms to ensure rapid and equitable access to medical countermeasures,' he said. Tomislav Sokol, MEP and member of the European Parliament's SANT Committee, has called for a comprehensive overhaul of the EU's approach to health innovation and preparedness, urging policymakers to focus on research, industrial resilience, and strategic autonomy. Sokol stressed the importance of stimulating funding for basic research and incentivising pharmaceutical innovation, while also ensuring that companies developing new medical products remain anchored in Europe. He welcomed recent EU initiatives, including the General Pharmaceutical Legislation (GPL) and the Critical Medicines Alliance (CMA), which he said are 'giving preferential treatment to production in Europe.' He also praised the establishment of the Health Emergency Preparedness and Response Authority (HERA) and its coordination efforts. However, he argued that further steps are needed. 'I think we have to do some additional things like stronger or mandatory coordination of stockpiling,' he said. Concluding on an optimistic note, Sokol stated: 'If we understand that healthcare and public health should be one of the priority sectors now in the EU, we can really make a difference, and that Europe can be much better prepared for future health crisis and also much less dependent on imports than it is now.' Central role of funding Emmanuel André, Co-Chair of the European Commission's Advisory Committee on Public Health Emergencies (ACPHE) and Professor of Clinical Microbiology at KU Leuven, underscored the central role of funding in Europe's ability to respond to future health threats. 'Funding is the key. If you want to get new medical countermeasures, antibiotics or therapeutics or vaccines, it is, as we say in French, 'nerf de la guerre.' It's really the key,' André said. He called for health to be prioritised in the EU's next Multiannual Financial Framework (MFF), urging the European Parliament, Council, and member states to ensure adequate budgetary support. 'We count on the European Parliament to help us on the Council and member states to make sure that we have sufficient budget to do what we're supposed to do,' he added. However, André warned that Europe cannot shoulder the burden alone. 'Europe should not fund everything. I call for all of the funders to come into the game. It's always the same players – the Gates Foundation, the Wellcome Trust are always there. But it's always the same,' he said. Pointing to recent international engagement, he questioned the financial follow-through. "Saudi Arabia held a nice ministerial meeting on AMR in Jeddah last November. Where is the money from Saudi Arabia? Where is the funding?' he asked. Framing antimicrobial resistance (AMR) as a global challenge, André concluded: 'This is a global issue, and we are not the only ones who have high GDP per capita. There are some others. So it's really a global, worldwide issue, and others also need to play their game.' Robust policy framework needed Huw Tippett, CEO of Shionogi Europe and board member since 2019, has urged policymakers to elevate health on the political agenda and implement robust frameworks to support antimicrobial innovation. Speaking on the pharmaceutical industry's role in combating antimicrobial resistance (AMR), Tippett highlighted the economic and structural challenges that hinder progress. 'We need a robust policy framework, including the right funding mechanisms, as sometimes the business case doesn't add up for pharma companies. We need equity in terms of access. All in all, health needs to be higher up the political agenda,' he said. Founded nearly 150 years ago in Osaka, Shionogi is one of the few major pharmaceutical firms maintaining a long-standing commitment to anti-infective research, with over six decades of experience in antimicrobial development. Tippett pointed to the '100 Day Mission' as a strategic model for future preparedness. 'I think that's an excellent strategic framework. There's a lot that has to be done in it. We've said it already today, we need excellent R&D pipelines through funding and investment, attracting more people back to the space,' he noted. He also stressed the importance of collaboration, particularly with organisations like the Global Antibiotic Research & Development Partnership (GARDP). 'Great funding mechanisms, working together, working as partners and getting to places in the world that you might not be able to get to yourself through great partnerships, such as Shionogi with GARDP. We're experts in the developed world, but GARDP are experts in the low and middle income world,' Tippett said, 'access to medicines is key.' [Edited By Brian Maguire | Euractiv's Advocacy Lab ]

Breaking the chain: strengthening Europe's preparedness for disease outbreaks
Breaking the chain: strengthening Europe's preparedness for disease outbreaks

Euractiv

time2 days ago

  • Euractiv

Breaking the chain: strengthening Europe's preparedness for disease outbreaks

Preventing future pandemics means preparing for both known and unknown viral disease threats. Since it was added to the WHO R&D Blueprint list of diseases in 2018, 'Disease X' has become the 'bogeyman' for scientists and health professionals across the globe. Disease X refers to an unexpected and unknown outbreak of a contagious or infectious disease that could cause a pandemic similar in scale to COVID-19. As an elusive pathogen, we don't know if we can prevent the occurrence of Disease X, but we do know that from SARS to MERS, swine flu, Ebola, and avian influenza, animal-borne diseases have been the source of every major pandemic in the past century. As a zoonotic disease is likely the prime candidate for the next pandemic, work should begin with a better understanding of the risks of emergence of zoonotic infectious diseases. Whilst the recently published WHO Pandemic Agreement calls on governments to take measures to identify and address drivers of infectious disease at the human-animal-environment interface, with the aim of early prevention of pandemics, the EU Preparedness Union Strategy makes no mention of animal health or zoonotic disease threats. The concrete role of the animal health sector in the EU Health Emergency Preparedness and Response Authority (HERA) is also not yet clearly defined. 'One Health' — integrating human, animal and environmental health — is of course mentioned by both the WHO and HERA, but investment in the prevention of animal-borne diseases, or zoonoses, as well as veterinary science and animal health more generally, is all too often overlooked in preparedness planning. A 2022 World Bank report estimated that investing US$10–11 billion annually in One Health prevention - including US$2.1 billion per year to bring public veterinary services up to international standards, and US$5 billion to improve farm biosecurity - could prevent pandemics that would carry vastly higher costs to manage and control. If we take the COVID-19 pandemic as an example, the International Monetary Fund's World Economic Outlook (IMF 2022) projected the cumulative output loss from the pandemic through 2024 to be about US$13.8 trillion. COVID-19's enduring devastation serves as a stark reminder of a critical and persistent risk: the systemic neglect of animal health systems. So, if we are serious about taking the necessary measures to prevent the next pandemic, we must learn from past failures and act both accordingly and decisively. This starts with better prioritising animal health for the benefits it can bring as our frontline of defence protecting against future pandemics. In today's interconnected world, a health risk in one location, in one species, is a risk for all due to globalised markets and travel, and the ability of pathogens to spread through various means, including direct contact, indirect contact, airborne transmission, and via vectors like insects. To bolster global health security, it is imperative to incorporate binding infrastructure and workforce provisions, including veterinary capacity and flexible regulation for rapid response to disease outbreaks, into preparedness planning. With over three-quarters of emerging infectious diseases coming from zoonotic pathogens, it is clear that we must enhance existing animal disease surveillance systems so they can identify potential threats to animal and human health in good time. We also need to increase the number of qualified vets and veterinary paraprofessionals and support animal owners' access to veterinary services. And with one in five farm animals lost due to disease each year, access to safe and effective vaccines and medicines for animals, as well ability to use these must be assured. With Europe facing numerous outbreaks of animal diseases such as bird flu, foot-and-mouth disease, and bluetongue virus, there is a clear need to implement disease prevention programmes, endorse the use of preventive measures such as vaccines and parasite control, and enhance basic animal health care. Although bluetongue and FMD are not zoonotic, bird flu is. Fortunately the risk of human infection remains low, but it has been reported in dairy cattle in the US. Without wishing to be alarmist, the EU and international governments need to realise that the more animals are affected by a disease, the greater the possibility for the virus to jump from mammal to mammal, and potentially also to people. Enhancing efforts in the field of animal disease prevention would not only reduce the huge socio-economic costs associated with a more reactive approach to disease outbreaks in animals, but they could also drastically reduce the potential One Health risks. Investing in animal health is non-negotiable. It's one of the most effective, proactive and lucrative investment strategies for enhanced preparedness we can take to stop emerging diseases before they ever endanger people and their livelihoods.

Ireland launches long-term sexual health strategy amid rising STI rates
Ireland launches long-term sexual health strategy amid rising STI rates

Euractiv

time3 days ago

  • Euractiv

Ireland launches long-term sexual health strategy amid rising STI rates

Ireland has unveiled a sweeping new National Sexual Health Strategy aimed at transforming access to sexual health services over the next decade, with a strong emphasis on prevention, equity, and integration across the healthcare system. The strategy, covering the period from 2025 to 2035, was launched by Minister for Health Jennifer Carroll MacNeill and Minister of State for Public Health, Wellbeing and the National Drugs Strategy Jennifer Murnane O'Connor. It sets out a comprehensive framework to address the evolving challenges of sexual health in Ireland, including rising rates of sexually transmitted infections (STIs), persistent stigma, and unequal access to care. 'This comprehensive Strategy reflects the evolving opportunities and challenges we face and outlines the steps we must take to ensure a healthier future for everyone, no matter their age, gender, orientation, ethnicity, or background,' said Carroll MacNeill at the launch. 'Our focus now is on continuing to develop and expand services that meet the needs of our population at every stage of life.' Access to services The strategy builds on the foundation of the 2015-2020 plan, which was extended during the Covid-19 pandemic. It introduces four core goals: promoting sexual health education, expanding equitable access to services, supporting reproductive choice, and strengthening surveillance and research. The first of three action plans, covering 2025–2028, was published alongside the strategy and outlines immediate implementation steps. Among the key measures are expanded access to contraception through the Free Contraception Scheme, increased availability of STI testing - including home testing kits - and enhanced support for HIV prevention and treatment, including Pre-Exposure Prophylaxis (PrEP) and Post-Exposure Prophylaxis (PEP). The strategy also commits to developing a new Model of Care for sexual health services, with a focus on geographic equity and integration into primary care. Murnane O'Connor described the strategy as 'a significant step forward in our efforts to protect and promote sexual health and wellbeing for everyone living in Ireland.' 'This Strategy reflects a modern, inclusive and evidence-based approach, one that empowers people with the information, access and support they need to make informed choices and avoid unnecessary risks, while supporting healthy relationships,' she said. Supporting justice sector The strategy also includes a commitment to support the Justice sector and Cuan in preventing domestic, sexual and gender-based violence (DSGBV), and to align with Ireland's international obligations under EU, UN, and WHO frameworks. The Irish Pharmacy Union (IPU) welcomed the strategy, highlighting the increasingly central role of community pharmacies in delivering sexual health services. 'As the most accessible healthcare providers, Irish community pharmacies play an increasingly important role in delivering sexual health services as part of community-based healthcare,' an IPU spokesperson said. Pharmacists already provide emergency contraception without prescription, dispense free contraception to women aged 17–35 under the HSE-funded scheme, and offer confidential consultations on STI prevention and treatment. They also dispense PrEP to eligible individuals and administer HPV vaccines privately to those aged 16–44. Empowering pharmacists The IPU said it was particularly encouraged by proposals to empower pharmacists to initiate and extend prescriptions for contraception and to dispense PEP, especially in rural or out-of-hours settings. 'This expanded role is welcomed and promises to enhance the sexual health services provided by pharmacies,' the spokesperson said. 'However, adequate resourcing is essential to ensure its success.' Europe's rising STI rates The strategy's publication comes amid growing concern across Europe about rising STI rates and uneven access to prevention and treatment services. According to the European Centre for Disease Prevention and Control (ECDC), infections such as gonorrhoea, syphilis, and chlamydia are increasing in nearly all EU/EEA countries, with significant variation in national responses. Northern and Western European countries - including Sweden, the Netherlands, and Germany - have led the way with comprehensive sexual education and robust public health campaigns. In contrast, several Southern and Eastern European nations continue to face cultural and financial barriers to implementing similar measures. Access to HIV prevention tools such as PrEP also varies widely. France, Germany, and Spain have established national programmes with strong uptake, while many Central and Eastern European countries lack formal initiatives due to regulatory or funding constraints. Surveillance systems are similarly inconsistent. Nordic countries maintain real-time data collection, while others struggle with underreporting and limited laboratory capacity. The ECDC has warned that antimicrobial resistance in gonorrhoea is an emerging threat and has called for greater harmonisation of policies and improved access to services across the bloc. Ireland's new strategy aligns with these EU-wide priorities, particularly in its emphasis on integrated care, expanded access, and data-driven policy. The government has committed to cross-sectoral collaboration and public engagement in shaping the next two action plans, due in 2028 and 2031. 'The urgency of coordinated action is clear,' said Professor Mary Horgan, Ireland's Interim Chief Medical Officer. 'Sexual health is a key part of overall health and wellbeing, but also of wider public health and of infection control.' With the publication of the National Sexual Health Strategy 2025–2035, Ireland has positioned itself at the forefront of a renewed European effort to address sexual health with clarity and inclusivity.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store